Search

Your search keyword '"Shiraishi, Taizo"' showing total 589 results
Start Over Author "Shiraishi, Taizo"
589 results on '"Shiraishi, Taizo"'

2. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy

Author

Nagata, Yasuhiro, Kageyama, Shinichi, Ishikawa, Takeshi, Kokura, Satoshi, Okayama, Tetsuya, Abe, Tetsuya, Murakami, Masahiko, Otsuka, Koji, Ariyoshi, Tomotake, Kojima, Takashi, Taniguchi, Ken, Kobayashi, Shinichiro, Shimada, Hideaki, Yajima, Satoshi, Suzuki, Takashi, Hirano, Satoshi, Tsuchikawa, Takahiro, Shichinohe, Toshiaki, Ueda, Shugo, Kanetaka, Kengo, Yoneda, Akira, Wada, Hisashi, Doki, Yuichiro, Yamaue, Hiroki, Katsuda, Masahiro, Ohi, Masaki, Yasuda, Hiromi, Kondo, Ken, Kataoka, Masato, Kodera, Yasuhiro, Koike, Masahiko, Shiraishi, Taizo, Miyahara, Yoshihiro, Goshima, Naoki, Fukuda, Eriko, Yamaguchi, Kei, Sato, Eiichi, Ikeda, Hiroaki, Yamada, Tomomi, Osako, Masaharu, Hirai, Kaoru, Miyamoto, Hiroshi, Watanabe, Takashi, and Shiku, Hiroshi

Published
2022
Full Text
View/download PDF

3. A simple risk stratification model for prostate cancer using histopathologic findings of radical prostatectomy.

Author

Semba, Remi, Uchida, Katsunori, Hirokawa, Yoshihumi, Shiraishi, Taizo, Onishi, Takehisa, Sasaki, Takeshi, Inoue, Takahiro, Watanabe, Masatoshi, and Miyamoto, Hiroshi

Subjects
RADICAL prostatectomy, SURGICAL margin, PREOPERATIVE care, PROSTATE cancer, LOG-rank test
Abstract

Objectives To develop a simple postoperative risk stratification based on histopathologic findings from radical prostatectomy specimens. Methods This study included 3 cohorts of patients with a preoperative diagnosis of clinically localized prostate cancer: 1 derivation cohort (n = 432) and 2 validation cohorts (n = 506 and n = 720). First, a postoperative risk stratification model was developed in the derivation cohort using the factors extraprostatic extension, surgical margin status, seminal vesicle invasion, and lymph node involvement. Each of the first 3 factors was assigned 0 or 1 point for negative or positive results, respectively, and the sum of the points, ranging from 0 to 3, was scored. pN1 was not scored but was analyzed separately. Validation cohorts were then used to evaluate the predictive accuracy of the model. Additionally, we compared the model with the Cancer of the Prostate Risk Assessment (CAPRA) score. Results Because the log-rank test showed no statistically significant differences between scores 1 vs 2 or score 3 vs pN1 in the derivation cohort, the following 3-level risk stratification was created: low risk (score 0), intermediate risk (score 1-2), and high risk (score 3 or pN1). There were statistically significant differences in recurrence-free survival between any of 2 groups of 3-level risk stratification. This model similarly worked in both validation cohorts. The C indexes for the model were higher than those for the CAPRA score. Conclusions This simple postoperative risk stratification model, based on radical prostatectomy findings, has a prognostic impact that has been validated in a multicenter population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

Author

Ishihara, Mikiya, Tono, Yasutaka, Miyahara, Yoshihiro, Muraoka, Daisuke, Harada, Naozumi, Kageyama, Shinichi, Sasaki, Takeshi, Hori, Yasuhide, Soga, Norihito, Uchida, Katsunori, Shiraishi, Taizo, Sato, Eiichi, Kanda, Hideki, Mizuno, Toshiro, Webster, Gill A., Ikeda, Hiroaki, Katayama, Naoyuki, Sugimura, Yoshiki, and Shiku, Hiroshi

Published
2020
Full Text
View/download PDF

7. Supplementary Figure S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

Author

Kageyama, Shinichi, primary, Ikeda, Hiroaki, primary, Miyahara, Yoshihiro, primary, Imai, Naoko, primary, Ishihara, Mikiya, primary, Saito, Kanako, primary, Sugino, Sahoko, primary, Ueda, Shugo, primary, Ishikawa, Takeshi, primary, Kokura, Satoshi, primary, Naota, Hiroaki, primary, Ohishi, Kohshi, primary, Shiraishi, Taizo, primary, Inoue, Naoki, primary, Tanabe, Masashige, primary, Kidokoro, Tomohide, primary, Yoshioka, Hirofumi, primary, Tomura, Daisuke, primary, Nukaya, Ikuei, primary, Mineno, Junichi, primary, Takesako, Kazutoh, primary, Katayama, Naoyuki, primary, and Shiku, Hiroshi, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

Author

Kageyama, Shinichi, primary, Ikeda, Hiroaki, primary, Miyahara, Yoshihiro, primary, Imai, Naoko, primary, Ishihara, Mikiya, primary, Saito, Kanako, primary, Sugino, Sahoko, primary, Ueda, Shugo, primary, Ishikawa, Takeshi, primary, Kokura, Satoshi, primary, Naota, Hiroaki, primary, Ohishi, Kohshi, primary, Shiraishi, Taizo, primary, Inoue, Naoki, primary, Tanabe, Masashige, primary, Kidokoro, Tomohide, primary, Yoshioka, Hirofumi, primary, Tomura, Daisuke, primary, Nukaya, Ikuei, primary, Mineno, Junichi, primary, Takesako, Kazutoh, primary, Katayama, Naoyuki, primary, and Shiku, Hiroshi, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure Legend from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

Author

Kageyama, Shinichi, primary, Ikeda, Hiroaki, primary, Miyahara, Yoshihiro, primary, Imai, Naoko, primary, Ishihara, Mikiya, primary, Saito, Kanako, primary, Sugino, Sahoko, primary, Ueda, Shugo, primary, Ishikawa, Takeshi, primary, Kokura, Satoshi, primary, Naota, Hiroaki, primary, Ohishi, Kohshi, primary, Shiraishi, Taizo, primary, Inoue, Naoki, primary, Tanabe, Masashige, primary, Kidokoro, Tomohide, primary, Yoshioka, Hirofumi, primary, Tomura, Daisuke, primary, Nukaya, Ikuei, primary, Mineno, Junichi, primary, Takesako, Kazutoh, primary, Katayama, Naoyuki, primary, and Shiku, Hiroshi, primary

Published
2023
Full Text
View/download PDF

13. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

Author

Okumura, Satoshi, primary, Ishihara, Mikiya, additional, Kiyota, Naomi, additional, Yakushijin, Kimikazu, additional, Takada, Kohichi, additional, Kobayashi, Shinichiro, additional, Ikeda, Hiroaki, additional, Endo, Makoto, additional, Kato, Koji, additional, Kitano, Shigehisa, additional, Matsumine, Akihiko, additional, Nagata, Yasuhiro, additional, Kageyama, Shinichi, additional, Shiraishi, Taizo, additional, Yamada, Tomomi, additional, Horibe, Keizo, additional, Takesako, Kazuto, additional, Miwa, Hiroshi, additional, Watanabe, Takashi, additional, Miyahara, Yoshihiro, additional, and Shiku, Hiroshi, additional

Published
2022
Full Text
View/download PDF

17. A Case of de novo Neuroendocrine Prostate Cancer

Author

Kise, Hideaki and Shiraishi, Taizo

Subjects
Neuroendocrine prostate cancer, 494.9
Abstract

A 56-year-old man visited our hospital with a chief complaint of worsening urinary pain after a treatment by another doctor. Prostate specific antigen (PSA) was 429.66 ng/ml, and computed tomography (CT) revealed multiple lymph node enlargement and multiple bone metastases. Prostatic adenocarcinoma (Gleason score 4＋5) was detected on the first prostate biopsy. Based on these results, the clinical stage was determined to be cT4N1M1b Androgen deprivation therapy (ADT) was started, and PSA decreased to 0.03 ng/ml at 3 months, but micturition and perineal pain tended to worsen, and multiple liver metastases were confirmed on CT. The second biopsy examination was performed and a diagnosis of neuroendocrine prostate cancer (NEPC) was made. Chemotherapy for small cell lung cancer was immediately performed, but no response was seen, and he died 8 months after the first visit. Immunostaining of prostate tissue of the first biopsy revealed that de novo NEPC expressed both PSA and synaptophysin in tumor cells.

Published
2021

31. This title is unavailable for guests, please login to see more information.

Author

Kise, Hideaki, Shiraishi, Taizo, Kise, Hideaki, and Shiraishi, Taizo

Abstract

A 56-year-old man visited our hospital with a chief complaint of worsening urinary pain after a treatment by another doctor. Prostate specific antigen (PSA) was 429.66 ng/ml, and computed tomography (CT) revealed multiple lymph node enlargement and multiple bone metastases. Prostatic adenocarcinoma (Gleason score 4＋5) was detected on the first prostate biopsy. Based on these results, the clinical stage was determined to be cT4N1M1b Androgen deprivation therapy (ADT) was started, and PSA decreased to 0.03 ng/ml at 3 months, but micturition and perineal pain tended to worsen, and multiple liver metastases were confirmed on CT. The second biopsy examination was performed and a diagnosis of neuroendocrine prostate cancer (NEPC) was made. Chemotherapy for small cell lung cancer was immediately performed, but no response was seen, and he died 8 months after the first visit. Immunostaining of prostate tissue of the first biopsy revealed that de novo NEPC expressed both PSA and synaptophysin in tumor cells.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results